title: Chemosensitivity in ovarian metastases from gastric cancer: a case series.
abstract: The development of ovarian metastases from gastric cancer indicates a turning point of the disease progression and is usually associated with poor prognosis. Efficacy of modern chemotherapy protocols in ovarian metastases from gastric cancer is unknown. In this case series, we have evaluated the chemosensitivity of ovarian metastases from gastric cancer in eight consecutive patients treated in our institution between January 2000 and April 2012. Median age at gastric cancer diagnosis was 48.3 years and ovarian metastases were mainly metachronous (88%). Patients were treated with FOLFOX or FOLFIRI protocols in first-line and with EOX protocol in second-line chemotherapy. These protocols of chemotherapy used in first- and second-line treatment were able to control the disease in 33.3% for ovarian metastases compared to 66.7% for extraovarian metastases. Mean overall survival (OS) from ovarian metastases diagnosis was 14.2 months. The four patients treated by bilateral oophorectomy had a longer mean OS (16 months) than the four patients who did not experienced surgery (12.3 months). In conclusion, this case series suggests that ovarian metastases from gastric cancer are less sensitive than extraovarian metastases to modern protocol of chemotherapy. To confirm these observations, a large retrospective study is ongoing.
authors.affiliation: Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, University of Paris Descartes, 20, rue Leblanc, 75015 Paris, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Brieau
authors.forename: Hélène
authors.initials: H
authors.lastname: Roussel
authors.forename: Theofano
authors.initials: T
authors.lastname: Markoutsaki
authors.forename: Olivier
authors.initials: O
authors.lastname: Dubreuil
authors.forename: Isabelle
authors.initials: I
authors.lastname: Trouilloud
authors.forename: Bruno
authors.initials: B
authors.lastname: Landi
authors.forename: Céline
authors.initials: C
authors.lastname: Lepère
authors.forename: Jean-Nicolas
authors.initials: JN
authors.lastname: Vaillant
authors.forename: Anne
authors.initials: A
authors.lastname: Berger
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
authors.forename: Julien
authors.initials: J
authors.lastname: Taieb
authors.forename: Aziz
authors.initials: A
authors.lastname: Zaanan
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002277:Carcinoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000556:secondary* / Q000628:therapy*; D010052:Ovariectomy; D013274:Stomach Neoplasms / Q000473:pathology*
chemical_list: D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin